FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896468068> ?p ?o ?g. }

• W2896468068 abstract "Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and 18F-fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG PET-CT). Accurate response prediction could lead to a patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant treatment in case of non-pCR.The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and 18F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points (before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the model for pCR prediction. Secondary endpoints include progression-free and overall survival.If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped.The article reports on a health care intervention on human participants and was prospectively registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341 ." @default.
• W2896468068 created "2018-10-26" @default.
• W2896468068 creator A5010863711 @default.
• W2896468068 creator A5011548156 @default.
• W2896468068 creator A5011998830 @default.
• W2896468068 creator A5015997023 @default.
• W2896468068 creator A5016282679 @default.
• W2896468068 creator A5016958906 @default.
• W2896468068 creator A5018329005 @default.
• W2896468068 creator A5020649524 @default.
• W2896468068 creator A5024165425 @default.
• W2896468068 creator A5025180096 @default.
• W2896468068 creator A5025225016 @default.
• W2896468068 creator A5030570166 @default.
• W2896468068 creator A5031748554 @default.
• W2896468068 creator A5036227908 @default.
• W2896468068 creator A5037416658 @default.
• W2896468068 creator A5040025434 @default.
• W2896468068 creator A5044517920 @default.
• W2896468068 creator A5044888519 @default.
• W2896468068 creator A5046588150 @default.
• W2896468068 creator A5047489509 @default.
• W2896468068 creator A5056059665 @default.
• W2896468068 creator A5061493410 @default.
• W2896468068 creator A5061692651 @default.
• W2896468068 creator A5065993006 @default.
• W2896468068 creator A5070504139 @default.
• W2896468068 creator A5072249743 @default.
• W2896468068 creator A5078429982 @default.
• W2896468068 creator A5082207699 @default.
• W2896468068 creator A5082821365 @default.
• W2896468068 creator A5090711824 @default.
• W2896468068 creator A5060519519 @default.
• W2896468068 date "2018-10-20" @default.
• W2896468068 modified "2023-10-18" @default.
• W2896468068 title "Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study" @default.
• W2896468068 cites W1940086102 @default.
• W2896468068 cites W1976922863 @default.
• W2896468068 cites W1977468182 @default.
• W2896468068 cites W1984901170 @default.
• W2896468068 cites W1986897680 @default.
• W2896468068 cites W1988303638 @default.
• W2896468068 cites W2003097139 @default.
• W2896468068 cites W2006940889 @default.
• W2896468068 cites W2027576789 @default.
• W2896468068 cites W2031936372 @default.
• W2896468068 cites W2034071374 @default.
• W2896468068 cites W2035106236 @default.
• W2896468068 cites W2037668591 @default.
• W2896468068 cites W2054305985 @default.
• W2896468068 cites W2061467946 @default.
• W2896468068 cites W2073140876 @default.
• W2896468068 cites W2075697465 @default.
• W2896468068 cites W2088783247 @default.
• W2896468068 cites W2099708392 @default.
• W2896468068 cites W2100697007 @default.
• W2896468068 cites W2115072149 @default.
• W2896468068 cites W2117231063 @default.
• W2896468068 cites W2121412644 @default.
• W2896468068 cites W2135386113 @default.
• W2896468068 cites W2139210276 @default.
• W2896468068 cites W2145440884 @default.
• W2896468068 cites W2146834306 @default.
• W2896468068 cites W2148287035 @default.
• W2896468068 cites W2154444715 @default.
• W2896468068 cites W2163234801 @default.
• W2896468068 cites W2176104799 @default.
• W2896468068 cites W2315074612 @default.
• W2896468068 cites W2330455963 @default.
• W2896468068 cites W2415390398 @default.
• W2896468068 cites W2528857721 @default.
• W2896468068 cites W2547418537 @default.
• W2896468068 cites W2554980426 @default.
• W2896468068 cites W2743627076 @default.
• W2896468068 cites W2753569256 @default.
• W2896468068 cites W2757383750 @default.
• W2896468068 cites W2760791435 @default.
• W2896468068 cites W2786274888 @default.
• W2896468068 cites W2788485956 @default.
• W2896468068 cites W2792936259 @default.
• W2896468068 cites W2795892743 @default.
• W2896468068 cites W2805710293 @default.
• W2896468068 cites W3020992444 @default.
• W2896468068 cites W4233026002 @default.
• W2896468068 doi "https://doi.org/10.1186/s12885-018-4892-6" @default.
• W2896468068 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6195948" @default.
• W2896468068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30342494" @default.
• W2896468068 hasPublicationYear "2018" @default.
• W2896468068 type Work @default.
• W2896468068 sameAs 2896468068 @default.
• W2896468068 citedByCount "51" @default.
• W2896468068 countsByYear W28964680682019 @default.
• W2896468068 countsByYear W28964680682020 @default.
• W2896468068 countsByYear W28964680682021 @default.
• W2896468068 countsByYear W28964680682022 @default.
• W2896468068 countsByYear W28964680682023 @default.
• W2896468068 crossrefType "journal-article" @default.
• W2896468068 hasAuthorship W2896468068A5010863711 @default.
• W2896468068 hasAuthorship W2896468068A5011548156 @default.
• W2896468068 hasAuthorship W2896468068A5011998830 @default.

• next